Cambridge Healthtech Institute (CHI) announces its third annual Accelerating Proof-of-Concept conference, to be held on October 3-5, 2011 at the Crowne Plaza Hotel Downtown in Philadelphia, PA. The conference will approach proof-of-concept from multiple angles:
• Early development
It will include presentations from industry leaders, commentary from global regulators and strategy discussions throughout. Topics include data analysis for decision making, surrogate endpoints, reducing attrition, and more. The keynote presentations will be delivered by Antonio (Tito) Fojo, M.D., Ph.D., Head, Experimental Therapeutics Section, NCI, NIH; and, Neeta Amin, Ph.D., Director, CVMED Research Unit, Pfizer.
In addition, a pre-conference short course titled “A Reasoned Approach to Decision Making” will be hosted by John Arrowsmith, Ph.D., Science Director, Europe Thomson Life Sciences Consulting, and Richard K. Harrison, Ph.D., Scientific Director, North America, Thomson Life Sciences Consulting. Delegates have an opportunity to participate in roundtable forums on defining proof of concept, while networking with peers and industry leaders.
For more information and to register, please visit healthtech.com/pfc
To inquire about sponsoring and/or exhibiting, contact Carol Dinerstein, 781-972-5471, dinerstein[.]healthtech.com.
Writers and editors are encouraged to attend. To request a press pass, contact Tracey Fielding at tfielding[.]healthtech.com.
About Cambridge Healthtech Institute (CHI)
Cambridge Healthtech Institute (chicorporate.com) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.
Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.